Table 1 Indications for viability studies and final late gadolinium enhancement (LGE) findings.
Indication for viability study | n = 70 | Final LGE findings | n = 33 |
|---|---|---|---|
Ischemic cardiomyopathy | 19 (27.1%) | Ischemic cardiomyopathy | 13 (39.4%) |
Non-ischemic cardiomyopathies | 51 (72.9%) | Non-ischemic cardiomyopathies | 20 (60.6%) |
 (Peri-) Myocarditis | 18 (35.3%) |  (Peri-) Myocarditis | 11 (55.0%) |
 Structural heart disease | 9 (17.6%) |  Sarcoidosis | 3 (15.0%) |
 Sarcoidosis | 7 (13.7%) |  Dilated cardiomyopathy | 2 (10.0%) |
 Dilated cardiomyopathy | 6 (11.8%) |  Hypertrophic cardiomyopathy | 2 (10.0%) |
 Hypertrophic cardiomyopathy | 5 (9.8%) |  Amyloidosis | 1 (5.0%) |
 Amyloidosis | 3 (5.8%) |  Chemotherapy-induced cardiomyopathy | 1 (5.0%) |
 Chemotherapy-induced cardiomyopathy | 2 (3.9%) |  |  |
 Anderson-Fabry disease | 1 (2.0%) |  |  |